Current Report Filing (8-k)
January 10 2022 - 07:17AM
Edgar (US Regulatory)
0001745020false00017450202022-01-102022-01-10
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C.
20549
FORM 8-K
CURRENT REPORT
Pursuant to
Section 13 or 15(d)
of the Securities
Exchange Act of 1934
Date of Report (Date
Earliest Event Reported):
January 10, 2022
Theseus
Pharmaceuticals, Inc.
(Exact name of registrant as specified
in its charter)
|
|
|
|
|
|
|
Delaware
|
|
001-40869
|
|
83-0712806
|
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification
No.)
|
|
|
|
|
|
245 Main Street
Cambridge, Massachusetts
(Address of Principal Executive
Offices)
|
|
02142
(Zip Code)
|
(857) 400-9491
(Registrant’s telephone number,
including area code)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e- 4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange on
which registered
|
|
Common stock, par value
$0.0001 per share
|
|
THRX
|
|
The Nasdaq Stock Market
LLC
(Nasdaq Global Select Market)
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth
company ☒
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the
extended transition period for complying with any new or revised
financial accounting standards provided pursuant to
Section 13(a) of the Exchange
Act. ☐
On January 10, 2022, Theseus Pharmaceuticals, Inc. (the “Company”)
issued a press release announcing that the first patient has been
treated in the Phase 1 portion of the Company’s ongoing Phase 1/2
study to evaluate lead candidate, THE-630, in patients with
advanced gastrointestinal stromal tumors, as well as indicating its
expectations with respect to the presentation of initial data from
the Phase 1 portion of the clinical trial. A copy of the press
release is attached as Exhibit 99.1 to this Current Report on Form
8-K.
|
Item 9.01
|
Financial Statements and
Exhibits.
|
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, as amended, the registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly
authorized.
|
|
|
|
|
|
|
Theseus Pharmaceuticals, Inc.
|
|
|
|
|
|
By:
|
/s/ Bradford D. Dahms
|
|
|
|
Name: Bradford D. Dahms
|
|
|
|
Title: Chief Financial Officer
|
Date: January 10, 2022
Theseus Pharmaceuticals (NASDAQ:THRX)
Historical Stock Chart
From Apr 2022 to May 2022
Theseus Pharmaceuticals (NASDAQ:THRX)
Historical Stock Chart
From May 2021 to May 2022
